Table 1

	PD with pain n=68	PD without pain n=74	Control n=54	P value
Age(years)^a	66.85 ± 9.54	69.61±10.17	68.39±7.82	0.346
Gender (male %)^b	39(57.4)	43(58.1)	30(55.6)	0.155
Disease duration (months)^a	69.18±48.30	71.65±34.10		0.723
Age onset(years)^a	61.07±9.61	63.64±10.12		0.125
UPDRS I^a	3.66±2.33	1.95±1.68		0.000
UPDRS II^a	12.57±6.10	9.04±4.94		0.000
UPDRS III^a	25.13±12.60	20.27±10.95		0.015
UPDRS IV^a	2.18±2.47	0.92±1.50		0.000
H/Y stage^a	2.33±0.76	1.95±0.80		0.005
HRSD^a	15.54±8.82	7.41±6.22		0.000
MoCA^a	22.49±4.77	23.89±3.09		0.037
NMSQT^a	8.38±4.87	4.61±3.16		0.000
Daily equivalent levodopa dosage(mg)^a	313.92±189.50	375.35±250.10		0.104
Motor fluctuation (yes)^c	33	17		0.001
Dyskinesias (yes)^c	16	6		0.011

Table 1: Clinical features of patients and univariate statistical analysis, ^ameans and standard deviations; ^bpercentages; ^cnumber of patients say “yes”.